Tilray Brands, Inc. (2HQ.DE)
EUR 0.42
(0.58%)
EUR 0.42
(0.58%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 788.94 Million USD | 25.8% |
| 2022 | 627.12 Million USD | -0.2% |
| 2021 | 628.37 Million USD | 22.47% |
| 2020 | 513.08 Million USD | 31.23% |
| 2019 | 390.99 Million CAD | 123.11% |
| 2018 | 175.24 Million CAD | 512.12% |
| 2017 | 28.62 Million CAD | 88.71% |
| 2016 | 15.17 Million CAD | 134.62% |
| 2015 | 6.46 Million CAD | 1357.38% |
| 2014 | 443.7 Thousand CAD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 200.04 Million USD | -3.93% |
| 2023 Q1 | 176.94 Million USD | -3.93% |
| 2023 Q4 | 229.88 Million USD | 22.06% |
| 2023 Q3 | 188.34 Million USD | -2.8% |
| 2023 FY | 788.94 Million USD | 25.8% |
| 2023 Q2 | 193.77 Million USD | 9.51% |
| 2022 Q4 | 184.18 Million USD | 26.51% |
| 2022 FY | 627.12 Million USD | -0.2% |
| 2022 Q3 | 145.58 Million USD | 1.01% |
| 2022 Q2 | 144.13 Million USD | -5.92% |
| 2022 Q1 | 153.21 Million USD | -0.07% |
| 2021 FY | 628.37 Million USD | 22.47% |
| 2021 Q4 | 153.32 Million USD | 0.96% |
| 2021 Q1 | 168.02 Million USD | 18.13% |
| 2021 Q3 | 151.87 Million USD | -2.12% |
| 2021 Q2 | 155.15 Million USD | -7.66% |
| 2020 Q3 | 120.57 Million CAD | -2.48% |
| 2020 Q2 | 123.63 Million USD | 11.79% |
| 2020 FY | 513.08 Million USD | 31.23% |
| 2020 Q4 | 142.23 Million USD | 17.97% |
| 2020 Q1 | 110.59 Million USD | 0.79% |
| 2019 Q2 | 90.41 Million USD | -4.18% |
| 2019 Q3 | 107.39 Million USD | 18.78% |
| 2019 Q4 | 109.72 Million USD | 2.18% |
| 2019 FY | 390.99 Million CAD | 123.11% |
| 2019 Q1 | 94.35 Million USD | 1.81% |
| 2018 Q1 | 10.23 Million USD | 11.91% |
| 2018 FY | 175.24 Million CAD | 512.12% |
| 2018 Q4 | 92.68 Million USD | 65.6% |
| 2018 Q3 | 55.96 Million USD | 242.97% |
| 2018 Q2 | 16.31 Million USD | 59.45% |
| 2017 Q4 | 9.14 Million USD | 13.79% |
| 2017 FY | 28.62 Million CAD | 88.71% |
| 2017 Q3 | 8.03 Million USD | 21.62% |
| 2017 Q1 | 4.84 Million USD | 20.86% |
| 2017 Q2 | 6.6 Million USD | 36.29% |
| 2016 FY | 15.17 Million CAD | 134.62% |
| 2016 Q4 | 4.01 Million USD | 3.38% |
| 2016 Q1 | 3.34 Million CAD | 45.87% |
| 2016 Q3 | 3.88 Million USD | -0.25% |
| 2016 Q2 | 3.89 Million CAD | 16.39% |
| 2015 Q1 | 717.97 Thousand CAD | 78.38% |
| 2015 Q3 | 1.97 Million CAD | 30.46% |
| 2015 Q4 | 2.29 Million CAD | 15.87% |
| 2015 FY | 6.46 Million CAD | 1357.38% |
| 2015 Q2 | 1.51 Million CAD | 111.14% |
| 2014 Q4 | 402.5 Thousand CAD | 877.13% |
| 2014 Q3 | 41.19 Thousand CAD | -89.31% |
| 2014 Q2 | 385.44 Thousand CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 FY | 443.7 Thousand CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| MPH Health Care AG | 34.43 Million EUR | -2191.405% |
| Apontis Pharma AG | 36.96 Million EUR | -2034.364% |
| Dermapharm Holding SE | 1.13 Billion EUR | 30.511% |
| Evotec SE | 781.42 Million EUR | -0.962% |
| MERCK Kommanditgesellschaft auf Aktien | 20.99 Billion EUR | 96.242% |
| PharmaSGP Holding SE | 101.09 Million EUR | -680.366% |
| SynBiotic SE | 3.86 Million EUR | -20331.734% |